Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II, Single Arm Trial of Combination Sunitinib and Gemcitabine in Sarcomatoid and/or Poor-risk Patients With Metastatic Renal Cell Carcinoma

NCT00556049 is registered in ClinicalTrials.gov with Massachusetts General Hospital as lead sponsor.

NCT NCT00556049
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00556049 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II, Single Arm Trial of Combination Sunitinib and Gemcitabine in Sarcomatoid and/or Poor-risk Patients With Metastatic Renal Cell Carcinoma
Lead sponsor
Massachusetts General Hospital
Phase
Phase 2
Overall status
Completed
Start date
December 31, 2007
Completion date
December 31, 2014
Enrollment
72 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

neoplasm metastases, renal cell carcinoma